TY - JOUR AU - Fallah, Jaleh AU - Ahluwalia, Manmeet S. PY - 2019 TI - The role of immunotherapy in the management of patients with renal cell carcinoma and brain metastases JF - Annals of Translational Medicine; Vol 7, Supplement 8 (December 31, 2019): Annals of Translational Medicine Y2 - 2019 KW - N2 - Patients with metastatic renal cell carcinoma (mRCC) who have metastases to the brain have poor prognosis and median overall survival (OS) of 6 to 10 months (1,2). Local treatments such as surgical resection, stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) are the mainstay of treatment in these patients. UR - https://atm.amegroups.org/article/view/30842